FamiCord (V3V.DE) Stock Price
FamiCord Price
Over the last 18 years FamiCord grew revenue by 10.2% annually, reaching 88.17 M EUR. Earnings per share have grown at 4.5% per year over the last 11 years. For FamiCord, the net margin of -7.1% is up versus -13.8% a few years ago. At today's price the dividend yield works out to roughly 5.73%. The payout ratio is around 51% of earnings. The dividend has grown at 2.3% per year over the past 4 years. The consensus 12-month price target for FamiCord is 7.65 EUR, about 174.2% above where the stock trades today. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus.
FamiCord stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
FamiCord business model & stock analysis
Frequently asked questions about FamiCord
Vita 34 AG's business model focuses on stem cell banking and regenerative medicine. As a biotechnology company, Vita 34 AG specializes in the collection, processing, and storage of stem cells derived from umbilical cord blood. By offering parents the opportunity to preserve their newborn's cord blood, Vita 34 AG contributes to potential future medical treatments and therapies. Through extensive quality control and state-of-the-art technologies, Vita 34 AG ensures the safe and professional handling of stem cells. With a strong emphasis on research and development, Vita 34 AG continues to advance its expertise in regenerative medicine, aiming to harness the potential of stem cells for various health-related applications.
Vita 34 AG is primarily active in the biotechnology and healthcare industries.
The main competitors of Vita 34 AG in the market include Cryo-Save AG, Cryo-Vita GmbH, StemCyte Inc., LifeCell International Pvt. Ltd, and Cordlife Group Limited.
Vita 34 AG is a German company that specializes in the field of stem cell banking. Established in 1997, Vita 34 is one of the oldest and largest stem cell banks in Europe. The company provides individuals the opportunity to store stem cells from umbilical cord blood and tissue which can be used in potential future medical treatments. Vita 34 AG's vision has always been to contribute to the development of innovative medical therapies and improve the quality of life for patients. With a strong focus on research and technological advancements, Vita 34 AG continues to be a leading player in the stem cell industry.
Vita 34 AG has achieved significant milestones in its history. It is noteworthy that the company pioneered the storage of umbilical cord blood as regenerative medicine in Europe. With over 20 years of experience, Vita 34 has established itself as a leading provider of stem cell banking services, offering secure and reliable storage options for families. The company has successfully expanded its operation to various countries, including Austria, Switzerland, and Brazil. Vita 34 AG continues to invest in research and development, ensuring cutting-edge technologies and future advancements in the field of stem cell preservation.
Vita 34 AG is primarily present in Germany, Austria, Switzerland, and other European countries.
Vita 34 AG is a leading biotech company that specializes in stem cell banking. The company's corporate philosophy is based on three core values: responsibility, innovation, and quality. Vita 34 AG is committed to taking responsibility for the long-term health preservation of individuals and their families by offering secure and reliable stem cell storage solutions. Through constant innovation, the company strives to stay at the forefront of stem cell technologies, ensuring the highest standards of quality and safety. Vita 34 AG believes in the immense potential of stem cells and their ability to revolutionize medical treatments, making them a trusted and forward-thinking partner in the field of regenerative medicine.
Analysts currently set an average price target of 7.65 EUR for the FamiCord stock (median: 7.65 EUR), implying +175.2 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the FamiCord stock: 0 recommend buying, 3 holding and 4 selling. For 2026, analysts expect FamiCord to generate revenue of 85.00 M EUR and earnings per share of 0.01 EUR.
The FamiCord share (V3V.DE) is listed on 8 stock exchanges, including: London (0NLV.L), SIX (Zürich) (V3V.SW), XETRA (V3V.DE), Frankfurt (V3V.F), München (V3V.MU), Düsseldorf (V3V.DU), Hamburg (V3V.HM).
The Vita 34 AG is a leading company in the field of stem cell storage for medical purposes. The company's business model includes various divisions to provide its customers with tailored solutions for stem cell storage. The main division of Vita 34 is the storage of stem cells for newborns. In this case, the company extracts valuable stem cells from the umbilical cord of the newborn during umbilical cord blood donation and stores them properly in a specially developed cryogenic storage system. These stem cells can be used later for the treatment of life-threatening diseases. Vita 34 also offers a storage solution for adults. With peripheral stem cell storage, stem cells can be taken from an adult's blood and stored. These stem cells can be effectively used for the treatment of diseases such as cancer and autoimmune diseases. Another division of the company is the sale of stem cell products. Vita 34 offers various products derived from the body's own stem cell material. This includes, among other things, the VitaPlus umbilical cord blood serum as a cosmetic product for skincare and the VitaMine&More dietary supplement. Both products contain important components from stem cells that support the body's immune system and promote well-being. In addition, Vita 34 offers a comprehensive service platform that supports customers with all questions related to stem cell therapy. This includes, among other things, consultations with medical experts and support in finding suitable therapy centers and methods. The business model of Vita 34 AG is strongly focused on customer orientation. The company offers its customers tailored solutions for stem cell storage as well as comprehensive consulting and service. This makes the company a worldwide leading provider of stem cell-based solutions for medical purposes.
The expected revenue of FamiCord is 85.00 M EUR. This figure is based on current financial data and reflects the company's business performance.
The expected profit of FamiCord is 158,808.00 EUR. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of FamiCord is currently 306.25. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the FamiCord stock.
The price-to-sales ratio (P/S) of FamiCord is currently 0.57. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the FamiCord stock.
The Eulerpool Quality Score for FamiCord is 3/10.
The ISIN of FamiCord is DE000A0BL849. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of FamiCord is A0BL84. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of FamiCord is V3V.DE. The ticker symbol is used to trade FamiCord shares on the stock exchange.
FamiCord stock
FamiCord Peer Group
FamiCord Ticker
FamiCord FIGI
All fundamentals and in-depth analysis of FamiCord
Our stock analysis for FamiCord stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of FamiCord. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.